Provexis (FRA:NZCA) FCF Margin % : -15.78% (As of Sep. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Provexis FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Provexis's Free Cash Flow for the six months ended in Sep. 2023 was €-0.07 Mil. Provexis's Revenue for the six months ended in Sep. 2023 was €0.45 Mil. Therefore, Provexis's FCF Margin % for the quarter that ended in Sep. 2023 was -15.78%.

As of today, Provexis's current FCF Yield % is -2.80%.

The historical rank and industry rank for Provexis's FCF Margin % or its related term are showing as below:

FRA:NZCA' s FCF Margin % Range Over the Past 10 Years
Min: -14325 Med: -143.7 Max: -50.23
Current: -70.54

During the past 13 years, the highest FCF Margin % of Provexis was -50.23%. The lowest was -14325.00%. And the median was -143.70%.

FRA:NZCA's FCF Margin % is ranked worse than
87.21% of 1024 companies
in the Drug Manufacturers industry
Industry Median: 0.195 vs FRA:NZCA: -70.54

Provexis FCF Margin % Historical Data

The historical data trend for Provexis's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Provexis FCF Margin % Chart

Provexis Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

FCF Margin %

Get a 7-Day Free Trial

-119.47

-96.15

-51.87

-50.20

-133.71

Provexis Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
FCF Margin %	Get a 7-Day Free Trial															-45.53	-54.86	-86.34	-173.64	-15.78

Competitive Comparison of Provexis's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Provexis's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Provexis's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Provexis's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Provexis's FCF Margin % falls into.

Provexis FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Provexis's FCF Margin for the fiscal year that ended in Mar. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	-0.591	/	0.442
	=	-133.71 %

Provexis's FCF Margin for the quarter that ended in Sep. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-0.071	/	0.45
	=	-15.78 %

Provexis FCF Margin % Related Terms

Thank you for viewing the detailed overview of Provexis's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Provexis (FRA:NZCA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Provexis PLC (FRA:NZCA) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

PXS.GB:UK PXS:UK

Address

2 Blagrave Street, I Ford, Reading, Berkshire, GBR, RG1 1AZ

Website

https://www.provexis.com

Provexis PLC is a British food company. It is engaged in developing and licensing the Fruitflow, which is a patented, natural, breakthrough ingredient which helps with platelet aggregation. Fruitflow reduces the propensity for aberrant blood clotting, typically associated with cardiovascular disease, which can result in heart attack and stroke. The extract is available in two formats, a syrup and a powder, and it can be included in a broad range of food, beverage and dietary supplement formats.

Provexis (FRA:NZCA) Headlines

No Headlines